

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

DR. REDDY'S LABORATORIES S.A. AND
DR. REDDY'S LABORATORIES, INC.
Petitioners,

v.

INDIVIOR UK LIMITED.
Patent Owner.

IPR2019-00329
Patent 9,687,454

PATENT OWNER RESPONSE

TABLE OF CONTENTS

I. INTRODUCTION 1

II. PROSECUTION HISTORY OF THE '454 PATENT..... 6

III. LEGAL STANDARD 7

IV. PETITIONERS FAIL TO SHOW THAT THE CHALLENGED CLAIMS ARE ANTICIPATED BY MYERS. 11

 A. The '571 Application Provides Written Description Support for the Claimed Polymer Weight Percentages. 11

 1. The Inventors Had Possession of the Claimed Polymer Weight Percentages. 11

 a. The '571 Application Provides Written Description Support for the Polymer Weight Percentage of “about 48.2 wt %” Recited in Claim 8. 12

 b. The '571 Application Provides Written Description Support for the Polymer Weight Percentage Range of “about 48.2 wt % to about 58.6 wt %” Recited in Claims 7 and 12. 14

 i. A POSA Would Have Understood that the Exemplary Formulations in Table 1 and Test Formulation 2 in Table 5 Pertain to the Same Invention and thus that the Inventors Possessed the Claimed Polymer Weight Percentage Range of “about 48.2 wt % to about 58.6 wt %.” 17

 ii. A POSA Would Have Understood from the Presence of Optional Ingredients that the Inventors Possessed the Claimed Polymer Weight Percentage Range of “about 48.2 wt % to about 58.6 wt %.” 18

- iii. A POSA Would Have Understood from the Disclosure of a Polymer Weight Percentage Range of 25% to About 58.6% that the Inventors Possessed the Claimed Polymer Weight Percentage Range of “about 48.2 wt % to about 58.6 wt %.” 21
- iv. In Similar Cases, Courts Have Found Adequate Written Description Support..... 22
- c. The ’571 Application Provides Written Description Support for the Polymer Weight Percentage Range of “about 40 wt % to about 60 wt %” Recited in Claim 1..... 29
 - i. A POSA Would Have Understood from the Presence of Optional Ingredients that the Inventors Possessed the Claimed Polymer Weight Percentage Range of “about 40 wt % to about 60 wt %.” 31
 - ii. A POSA Would Have Understood from the Disclosure of a Polymer Weight Percentage Range of 25% to About 60% that the Inventors Possessed the Claimed Polymer Weight Percentage Range of “about 40 wt % to about 60 wt %.” 31
- 2. Particular Polymer Weight Percentages and Bounded Polymer Weight Percentage Ranges Were an Aspect of the Inventive Films. 33
 - a. The ’571 Application Expressly Discloses Particular Polymer Weight Percentages. 34
 - b. The ’571 Application Discloses Bounded Polymer Weight Percentage Ranges. 35
 - c. The ’571 Application Discloses that the Polymer and Amount of Polymer Are Important to the Inventive Films. 39

d.	The '571 Application Discloses that the Inventors in Most Cases Kept the Polymer Weight Percentage of the Exemplary Films Constant.	41
e.	The Disclosed Testing's Focus on pH Does Not Detract from the Disclosed Importance of Polymer Weight Percentages to the Inventive Films.	44
B.	The '571 Application Provides Written Description Support for the Claimed Buprenorphine:Polymer / (b):(a) Ratios.	46
1.	The Inventors Had Possession of the Buprenorphine:Polymer Ratio Range of "about 1:3 to about 1:11.5."	46
2.	Buprenorphine:Polymer Ratios Were an Aspect of the Inventive Films.	48
a.	The '571 Application Discloses that Buprenorphine Is an Important Component of the Inventive Films.	49
b.	The '571 Application Discloses that the Polymer Is an Important Component of the Inventive Films.	50
c.	A POSA Would Have Noticed that the Inventors in Most Cases Kept the (b):(a) Ratio Consistent Across the Disclosed Formulations with Different Dosage Strengths.	51
d.	The '571 Application Discloses that the Inventors Scaled Up from the Unit Formulas in Tables 1 and 5.	52
e.	A POSA Would Have Understood that the Buprenorphine: Polymer Ratio Is Important to the Inventive Films in Light of the Disclosed Functions of the Polymer.....	53
f.	Petitioners' Arguments Lack Merit.	54
i.	<i>Purdue</i> Is Inapposite.....	54

ii.	A Claimed Ratio Need Not Be Recited Expressly in the Disclosure to Have Written Description Support.....	57
iii.	The Express Disclosure of Other Ratios Does Not Detract from the Disclosed Importance of the Buprenorphine: Polymer Ratio.	59
iv.	Petitioners’ Argument that the ’571 Application Discloses Unlimited Amounts of Buprenorphine and Polymer Is Irrelevant and Incorrect.....	60
V.	CONCLUSION.....	61

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.